219 related articles for article (PubMed ID: 34038589)
1. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer.
Moroney MR; Woodruff E; Qamar L; Bradford AP; Wolsky R; Bitler BG; Corr BR
Mol Carcinog; 2021 Aug; 60(8):511-523. PubMed ID: 34038589
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer.
Chan DW; Mak CS; Leung TH; Chan KK; Ngan HY
Oncotarget; 2012 Dec; 3(12):1546-56. PubMed ID: 23295859
[TBL] [Abstract][Full Text] [Related]
3. Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in
Corr BR; Moroney MR; Woodruff E; Watson ZL; Jordan KR; Danhorn T; Bailey C; Wolsky RJ; Bitler BG
bioRxiv; 2023 Apr; ():. PubMed ID: 37066339
[TBL] [Abstract][Full Text] [Related]
4. Investigations on the mechanism of progesterone in inhibiting endometrial cancer cell cycle and viability via regulation of long noncoding RNA NEAT1/microRNA-146b-5p mediated Wnt/β-catenin signaling.
Huang X; Zhong R; He X; Deng Q; Peng X; Li J; Luo X
IUBMB Life; 2019 Feb; 71(2):223-234. PubMed ID: 30452118
[TBL] [Abstract][Full Text] [Related]
5. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
De P; Carlson JH; Wu H; Marcus A; Leyland-Jones B; Dey N
Oncotarget; 2016 Jul; 7(28):43124-43149. PubMed ID: 27281609
[TBL] [Abstract][Full Text] [Related]
6. Expression and the clinical significance of Wnt10a and Wnt10b in endometrial cancer are associated with the Wnt/β-catenin pathway.
Chen H; Wang Y; Xue F
Oncol Rep; 2013 Feb; 29(2):507-14. PubMed ID: 23135473
[TBL] [Abstract][Full Text] [Related]
7. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
8. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.
Kim G; Kurnit KC; Djordjevic B; Singh C; Munsell MF; Wang WL; Lazar AJ; Zhang W; Broaddus R
Mod Pathol; 2018 Oct; 31(10):1553-1559. PubMed ID: 29795437
[TBL] [Abstract][Full Text] [Related]
9. Endometrium-derived mesenchymal stem cells suppress progression of endometrial cancer via the DKK1-Wnt/β-catenin signaling pathway.
Xu Y; Hu J; Lv Q; Shi C; Qiu M; Xie L; Liu W; Yang B; Shan W; Cheng Y; Zhao B; Chen X
Stem Cell Res Ther; 2023 Jun; 14(1):159. PubMed ID: 37287079
[TBL] [Abstract][Full Text] [Related]
10. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
11. Sesamolin serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3β/β-catenin signaling.
Lin Y; Chen X; Lin L; Xu B; Zhu X; Lin X
Cell Mol Biol Lett; 2024 May; 29(1):63. PubMed ID: 38698330
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NCAPG expression inactivates the Wnt/β-catenin signal to suppresses endometrial cancer cell growth in vitro.
Liu C; Yan Y; Di F; Li W; Yin X; Dong L
Environ Toxicol; 2021 Dec; 36(12):2512-2520. PubMed ID: 34480403
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA steroid receptor activator promotes the progression of endometrial cancer via Wnt/ β-catenin signaling pathway.
Park SA; Kim LK; Kim YT; Heo TH; Kim HJ
Int J Biol Sci; 2020; 16(1):99-115. PubMed ID: 31892849
[No Abstract] [Full Text] [Related]
14. TTK Inhibitors as a Targeted Therapy for
Zaman GJR; de Roos JADM; Libouban MAA; Prinsen MBW; de Man J; Buijsman RC; Uitdehaag JCM
Mol Cancer Ther; 2017 Nov; 16(11):2609-2617. PubMed ID: 28751540
[TBL] [Abstract][Full Text] [Related]
15. The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.
Berger AA; Kawaler EA; Dao F; Misirlioglu S; Fernandez EA; Olvera N; Van Oudenhove E; DeLair D; Levine DA
Gynecol Oncol; 2022 Nov; 167(2):323-333. PubMed ID: 36150916
[TBL] [Abstract][Full Text] [Related]
16. Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling.
Emons G; Spitzner M; Reineke S; Möller J; Auslander N; Kramer F; Hu Y; Beissbarth T; Wolff HA; Rave-Fränk M; Heßmann E; Gaedcke J; Ghadimi BM; Johnsen SA; Ried T; Grade M
Mol Cancer Res; 2017 Nov; 15(11):1481-1490. PubMed ID: 28811361
[TBL] [Abstract][Full Text] [Related]
17. SOX17 is a tumor suppressor in endometrial cancer.
Zhang Y; Bao W; Wang K; Lu W; Wang H; Tong H; Wan X
Oncotarget; 2016 Nov; 7(46):76036-76046. PubMed ID: 27738313
[TBL] [Abstract][Full Text] [Related]
18. The Role of CTNNB1 in Endometrial Cancer.
Ledinek Ž; Sobočan M; Knez J
Dis Markers; 2022; 2022():1442441. PubMed ID: 35531470
[TBL] [Abstract][Full Text] [Related]
19. CTNNB1 Knockdown Inhibits Cell Proliferation and Aldosterone Secretion Through Inhibiting Wnt/β-Catenin Signaling in H295R Cells.
Zhou T; Luo P; Wang L; Yang S; Qin S; Wei Z; Liu J
Technol Cancer Res Treat; 2020; 19():1533033820979685. PubMed ID: 33287648
[TBL] [Abstract][Full Text] [Related]
20. The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro.
Stakheev D; Taborska P; Strizova Z; Podrazil M; Bartunkova J; Smrz D
Sci Rep; 2019 Mar; 9(1):4761. PubMed ID: 30886380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
